Nanomedicine - Global Developments and Growth Opportunities

06-Jul-2004 - With the potential for targeted therapy, and therefore reduced side effects, nanomedicine holds the promise of significantly improving quality of life parameters. At the same time, the adoption of nanotechnology-based applications by large therapeutic and diagnostic companies is accelerating the ...

OctoPlus Grants SurModics Access to Two Biodegradable Polymer Families for Medical Device Applications

30-Jun-2004 - Leiden. OctoPlus, a drug delivery and development company, announced that it has granted SurModics, Inc., a leading provider of surface modification and drug delivery solutions to the medical device industry, an option to acquire an exclusive license to two novel classes of biodegradable polymers ...

Biochip Technology to Revolutionise the Pharmaceutical Industry

17-May-2004 - Advancements in biotechnology have culminated in its integration with semiconductor technologies such as micro-electromechanical systems, resulting in the evolution of biochips. Biochips provide pharma companies with sophisticated tools for speedy development of drugs and accurate diagnosis and ...

Elan Licenses Its NanoCrystal Technology to Roche

Proprietary Elan technology helps improve drug delivery by transforming drugs into more effective and 'user friendly' dosage forms to increase patient convenience and compliance

22-Apr-2004 - Athlone, Ireland. Elan Pharma International Ltd., a subsidiary of Elan Corporation plc, announced an agreement to license its proprietary NanoCrystal(TM) technology to Roche. NanoCrystal technology can improve the bioavailability of drugs by transforming them into nanometer-sized particles that ...

University of Ulster Opens Nanotechnology Research Institute

22-Apr-2004 - Belfast, Northern Ireland. The University of Ulster opened a new Nanotechnology Research Institute at its Jordanstown campus in Northern Ireland The GBP8m research institute will position Northern Ireland at the forefront of nanotechnology research in the UK, and will be a catalyst for the future ...

Angiotech extends exclusive licensing agreement with Poly-Med for biomaterial technologies

15-Apr-2004 - Vancouver. Angiotech Pharmaceuticals, Inc., a specialty pharmaceutical company focusing on drug-coated medical devices and biomaterials, today announced that it has licensed a portfolio of biomaterial, drug delivery, and medical device technologies from Poly-Med, Inc. This agreement will expand ...

SkyePharma to Receive Milestone Payment from Endo for Propofol IDD-D(TM)

Phase III Trials to Start by Mid-Year

08-Apr-2004 - London. SkyePharma PLC announces today that it has successfully completed the review of the Phase II trial results of Propofol IDD-D(TM) with the US Food & Drug Administration ("FDA"). Propofol IDD-D(TM) is licensed in North America to Endo Pharmaceuticals (NASDAQ:ENDP) ("Endo") and, under the ...

LAM Pharmaceutical Signs Distribution Agreement with China's Largest Pharmaceutical Firm

31-Mar-2004 - LAM Pharmaceutical, Corp., a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today that it has signed an agreement with China National Pharmaceutical Foreign Trade Corporation (Sinopharm Foreign Trade), a ...

Generex Biotechnology Corporation Granted Drug Delivery Patent in Australia

16-Mar-2004 - Toronto. Generex Biotechnology Corporation , a leader in the area of buccal drug delivery, announced that it has received Deed of Letters Patent #766745 from the Australian Patent Office. The patent entitled, "Pharmaceutical solubilized in aerosol propellant" relates to a formulation with a ...

Generex Biotechnology Announces Appointment of New Independent Director

13-Feb-2004 - Generex Biotechnology Corporation, a leader in the area of buccal drug delivery, announced the appointment of Mindy J. Allport-Settle as an independent member of the Company's board of directors effective February 6, 2004. Ms. Allport-Settle has been the President & Chief Executive Officer of ...